

**A SINGLE RESIDUE IN A NOVEL ADP-RIBOSYL CYCLASE CONTROLS PRODUCTION OF THE CALCIUM MOBILIZING MESSENGERS, CYCLIC ADP-RIBOSE AND NICOTINIC ACID ADENINE DINUCLEOTIDE PHOSPHATE.**

**Latha Ramakrishnan<sup>1</sup>, H el ene Muller-Steffner<sup>2</sup>, Christophe Bosc<sup>3</sup> Victor D. Vacquier<sup>4</sup>, Francis Schuber<sup>2</sup>, Marie-Jo Moutin<sup>3</sup>, Leslie Dale<sup>1</sup> and Sandip Patel<sup>1,5</sup>**

From <sup>1</sup>Department of Cell and Developmental Biology, University College London, London WC1E 6BT, UK, <sup>2</sup>Facult e de Pharmacie, Universit e de Strasbourg, 67400 Illkirch, France, <sup>3</sup>INSERM U836, Grenoble Institut des Neurosciences, CEA-iRTSV-GPC, Universit e Joseph Fourier, BP170, 38042 Grenoble, France, <sup>4</sup>Marine Biology Research Division, Scripps Institution of Oceanography, University of California San Diego, La Jolla, California 92093-0202, USA  
Running title: Molecular determinants of cADPR and NAADP production.

<sup>5</sup>Address correspondence to: Sandip Patel, PhD, Department of Cell and Developmental Biology, University College London, Gower Street, London WC1E 6BT, UK; email: patel.s@ucl.ac.uk

**Cyclic ADP-ribose and NAADP are ubiquitous calcium mobilizing messengers produced by the same family of multifunctional enzymes, the ADP-ribosyl cyclases. Not all ADP-ribosyl cyclases have been identified and how production of different messengers is achieved is incompletely understood. Here, we report the cloning and characterization of a novel ADP-ribosyl cyclase (SpARC4) from the sea urchin, a key model organism for the study of calcium signalling pathways. Like several other members of the ADP-ribosyl cyclase superfamily, SpARC4 is a glycoprotein targeted to the plasma membrane via a GPI anchor. However, unlike most other members, SpARC4 shows a remarkable preference for producing cyclic ADP-ribose over NAADP. Mutation of a single residue (tyrosine 142) within a non-canonical active site reversed this striking preference. Our data highlight further diversification of this unusual enzyme family, provide mechanistic insight into multifunctionality and suggest that different ADP-ribosyl cyclases are fine tuned to produce specific calcium mobilizing messengers.**

Changes in cytosolic calcium levels govern a multitude of cellular processes. Many extracellular stimuli mediate complex changes in calcium through production of second messengers (1). These molecules effect release of calcium from intracellular stores. In addition to inositol 1,4,5-trisphosphate, both cyclic ADP-ribose (cADPR) and nicotinic acid adenine dinucleotide phosphate (NAADP) play critical roles in the generation of agonist-evoked calcium signals (2;3). cADPR releases calcium through activation of the ryanodine receptors located on

endoplasmic reticulum stores (2;4). The mechanism of action of NAADP is less certain (5) although in sea urchin eggs, where its effects were discovered (6), it is clear that NAADP acts on novel calcium-permeable channels located not on the endoplasmic reticulum, but instead on acidic lysosomal-like stores (7-9). These channels have recently been identified as the two-pore channels (10-12). Remarkably, both cADPR and NAADP are synthesized by the same family of enzymes, the ADP-ribosyl cyclases (13;14), which therefore play a central role in calcium signalling and have been implicated in a variety of processes ranging from bacterial clearance (15) to social behaviour (16).

ADP-ribosyl cyclase activity was originally identified in sea urchin egg homogenates (17) but an enzyme with this activity was later purified (18) and cloned (19) from *Aplysia californica* ovotestes. This enzyme was shown to catalyze the cyclization of NAD to form cADPR (18;20) and the replacement of the nicotinamide moiety in NADP with nicotinic acid, to form NAADP (21). Based on sequence similarity, it became evident that the mammalian proteins, CD38 (22) and CD157 (23) were also ADP-ribosyl cyclases. More recently *SmNACE* (24), a homologue from the blood fluke *Schistosoma mansoni*, and an expanded family of three ADP-ribosyl cyclases (SpARC1-3) from the sea urchin (25) have been identified. Somewhat paradoxically, many members of the ADP-ribosyl cyclase family including CD38, the most extensively studied, are located predominantly on the cell surface and therefore away from their cytosolic substrates (13;14). This topological barrier however is circumvented through identified transporter molecules that mediate both substrate efflux and product influx across the plasma membrane (26). Recent studies

have also shown that members of the sea urchin ADP-ribosyl cyclase family are present within intracellular organelles where again they are able to access cytosolic substrates through presumed transporters (25;27). *Aplysia* ADP-ribosyl cyclase also appears to localize to cytoplasmic organelles in eggs (18) and has been shown more recently to undergo redistribution from the cytoplasm to the nucleus upon depolarisation in neurons (28). Targeting of ADP-ribosyl cyclase to different subcellular locales may therefore result in localised production of calcium mobilizing messengers which may contribute to the production of spatially restricted calcium signals.

Reduced cellular levels of cADPR (15;29;30) and NAADP (31) in certain tissues from CD38-knockout mice underscore the physiological importance of this ADP-ribosyl cyclase in generating calcium mobilizing messengers *in vivo*. Such analyses have also highlighted the likely existence of novel ADP-ribosyl cyclases in tissues such as the brain (32) and uterus (33) where messenger levels appear to be unperturbed in these animals. Indeed several novel activities (34-43) including a soluble enzyme in sea urchin eggs (44) have been described for which molecular correlates are currently lacking. It appears therefore that not all ADP-ribosyl cyclases have been described yet at the molecular level.

ADP-ribosyl cyclases show only modest sequence similarity (30-40%). However, their overall 3-D structures, where known, are almost identical (45-47). The active site has been defined for both *Aplysia* ADP-ribosyl cyclase (48) and CD38 (49) in which a highly conserved glutamate is likely the catalytic residue. Despite this conservation in 3D-structure, ADP-ribosyl cyclases show remarkable differences in their catalytic properties. For example, *Aplysia* ADP-ribosyl cyclase produces primarily cADPR from NAD (18;20) whereas, in contrast, CD38 possesses robust NAD glycohydrolase activity (22) thereby producing predominantly ADP-ribose and only modest amounts of cADPR (2-3 % of reaction products). Additionally, CD38 is capable of hydrolyzing cADPR directly to ADP-ribose, whereas *Aplysia* ADP-ribosyl cyclase is comparatively a very poor cADPR hydrolase (13;14;50). Notably, ADP-ribose also modulates calcium fluxes through regulation of the TRP channel, TRPM2 present in the plasma membrane (51) and possibly also on lysosomal calcium stores (52;53). Further differences in

catalytic activity of ADP-ribosyl cyclases are evident with the surrogate substrate, NGD (54). Both *SmNACE* (24) and *SpARC1* (25) although able to cyclize NGD to cGDPR, produce much less cADPR from NAD (24) than CD38 whereas *SpARC2* (55) and several unidentified mammalian ADP-ribosyl cyclases (32;36;39) are unable to cyclize NGD.

Understanding the molecular basis for such unprecedented differences in catalysis represents a key challenge that will ultimately aid in understanding the functions of these enzymes *in vivo*. Intriguingly, although glycohydrolase activity is very low for *Aplysia* ADP-ribosyl cyclase using the natural substrate, NAD, this activity is unmasked by the introduction into its structure of an additional cystine pair, as found in CD38 (56), and also by using a fluorinated analogue of NAD that cannot be cyclized (57). NAD glycohydrolase activity can also be readily detected in *Aplysia* ADP-ribosyl cyclase upon mutation of phenylalanine 174 which together with the associated reduction in cyclase activity results in a mutant enzyme displaying properties reminiscent of CD38 (58). Conversely, mutation of the corresponding residue (threonine 221) in CD38 increases cyclase activity at the expense of NAD glycohydrolase activity. Indeed, the concomitant mutation of this residue and of glutamate 146, a residue previously implicated in determining the cyclase/NAD glycohydrolase ratio (59), results in a catalytic profile very similar to that of *Aplysia* ADP-ribosyl cyclase including poor cADPR hydrolase activity (58). Mutagenesis of the *SmNACE* has also resulted in the identification of a single residue that increases ADP-ribosyl cyclase activity (60).

Although ADP-ribosyl cyclases are capable of synthesis of both cADPR and NAADP, how messenger production is controlled *in vivo* is not clear. It is possible that the activities of the same enzyme may be differentially regulated. Alternatively, different homologues may be endowed with different relative activities. Here we report the molecular cloning of *SpARC4*, a novel member of the ADP-ribosyl cyclase family from the sea urchin and show that this protein is a GPI-anchored plasma membrane glycoprotein capable of synthesising both cADPR and NAADP. In contrast to other ADP-ribosyl cyclases, and in analogy with the *Aplysia* enzyme, *SpARC4* preferentially produces cADPR. We identify a unique acidic-basic cluster of amino acids within

the N-terminus and a non-conserved tyrosine residue within the active site. Whereas manipulation of the former had little impact on catalysis, tyrosine 142 was found to control the relative production of cADPR and NAADP such that its mutation was sufficient to convert SpARC4 into an enzyme that preferentially produces NAADP.

## METHODS

*Molecular cloning of SpARC4* - The sequences of the primers used are listed in Table S1. Total RNA was isolated from prism stage (46 h) embryos of *Strongylocentrotus purpuratus* using the RNeasy kit (Qiagen), according to manufacturer's instructions. The samples were treated with DNase to eliminate any genomic DNA contamination. First strand cDNA synthesis was performed using the Improm-II kit (Promega) and either gene-specific primer 1R (for 5'-RACE) or oligo (dT)<sub>17</sub> adaptor primers (for 3'-RACE). Typical reactions (40 µl) contained 2 µg RNA. For 5'-RACE, the polyA tailing reaction was performed using terminal transferase (Promega) as per the manufacturer's instructions. Nested PCR was performed using the oligo (dT)<sub>17</sub> adaptor or adaptor primer as the forward primers with the gene-specific reverse primers 3R or 2R, respectively. A 750 bp product was amplified and sequenced. This extended the 5'-sequence to an in frame stop codon. For 3'-RACE, PCR was performed using the nested gene-specific forward primers 1F and 2F together with the adaptor primer as the reverse primer. A 850 bp product was amplified, which extended the 3'-sequence to an in-frame stop codon. All the above gene-specific primers were based on genomic contig 640882 identified by an initial BLAST search of the *Strongylocentrotus purpuratus* genome sequencing project at the Baylor College of Medicine

(<http://www.hgsc.bcm.tmc.edu/projects/seaurchi> n/) with the *Aplysia californica* ADP-ribosyl cyclase sequence (accession number: [P29241](#)). An additional pair of gene-specific primers 6F and 3' UTR 1R were designed on the sequences obtained by RACE and used to amplify the full-length coding sequence + 54 bp of 3'-UTR of SpARC4. The 1089 bp product was cloned into pCR<sup>®</sup>II-TOPO<sup>®</sup> (Invitrogen) and sequenced in both directions. The sequence was deposited at EMBL under the accession number FN645665. All PCRs were performed using Platinum Hi-

fidelity Taq DNA polymerase enzyme (Invitrogen) and 35 cycles of denaturation (30 sec at 94°C) annealing (30 sec at 50°C) and extension (1 min at 68°C) following an initial denaturation step (2 min at 94°C).

*Plasmids* - A plasmid encoding untagged SpARC4 was generated by amplification of the full-length coding sequence using primers 7F and 6R followed by cloning of the product into pCS2+ at the EcoRI and XbaI sites. Plasmids encoding for SpARC4, tagged at their N termini with 6 *myc* tags, were generated by cloning products in to the EcoRI and XbaI sites of pCS2+ MT into which the sequence corresponding to the signal peptide of SpARC2 (residues 1-23) had been inserted upstream of the *myc* tags at the BamHI and ClaI sites (25). Full-length (mature) SpARC4 (SpARC4 *myc*) was generated by inserting the product amplified using primer N-Myc 1F and 6R corresponding to amino acids 39 to 343. SpARC4 lacking the C-terminal 17 amino acids (SpARC4 ΔC *myc*) was generated by inserting the product amplified using primers N-Myc 1F and CT-Trun 1R corresponding to amino acids 39 to 326. SpARC4 lacking the N-terminal 17 amino acids from the mature SpARC4 (SpARC4 ΔN *myc*) was generated by inserting the product amplified using primer N-Myc 2F and 6R corresponding to amino acids 56 to 343. Plasmids encoding for SpARC4<sup>R52A/R53A</sup> *myc*, SpARC4<sup>Y142W</sup> *myc*, and SpARC4<sup>Y142H</sup> *myc* were constructed using the QuikChange site directed mutagenesis kit (Stratagene) with pCS2+ SpARC4 *myc* as the template and the following mutagenic primers: R52,53A\_sense / R52,53A\_antisense, Y142W\_sense / Y142W\_antisense and Y142H\_sense / Y142H\_antisense. All constructs were verified by DNA sequencing. The sequences of the primers used are listed in Table S1 and a schematic of the constructs is presented in Fig. 2B.

*Sequence analysis* - Sequences were aligned using Clustal-W. Signal peptides/anchors were predicted by SignalP 3.0. GPI modification site was identified by big-PI predictor and GPI-SOM. N-glycosylation sites were predicted by NetNGlyc 1.0. The pro-protease cleavage site was predicted by ProP 1.0.

*Microinjection of Xenopus laevis embryos* - *Xenopus* embryos at the 2-4 cell stage were injected with 0.8 ng of mRNA per blastomere

and cultured in 5% normal amphibian medium (61) at 14°C until the late blastula/early gastrula stage. For immunocytochemistry only a single blastomere was injected in order to induce mosaic expression.

*Transfection of HEK cells* - Human embryonic kidney (HEK) cells were grown and maintained in DMEM supplemented with 10% serum, penicillin (100 U/ml) and streptomycin (100 µg/ml) at 37°C in a humidified 5% CO<sub>2</sub> chamber. The cells were seeded in an antibiotic-free medium 24 h prior to transfection on either 6 well plates (for western blotting/secretion assays) or 24-well plates containing poly-L-Lysine (20 µg/ml) coated 1 cm diameter coverslips (for immuno-cytochemistry). Upon reaching 90% confluency, the cells were transiently transfected with plasmid DNA using Lipofectamine 2000 transfection reagent (Invitrogen) according to manufacturer's instructions. Cells were used 17 hours post-transfection.

*Preparation of homogenates* - For Western blot analysis, homogenates were prepared at 4°C in a buffer composed of 20 mM Tris,HCl pH 7.2, 50 mM NaCl, 10 mM MgAcetate and 1% Triton X-100. For *Xenopus* embryos, the embryos were resuspended at a ratio of 20 µl of buffer/embryo, incubated for 30 min and the supernatant collected following centrifugation at 21,000xg for 1 min. For HEK cells, cells were resuspended at a ratio of 100 µl of buffer/confluent well of a 6-well plate, incubated for 60 min and the supernatant collected following centrifugation at 100,000xg for 60 min. For enzyme activity measurements, *Xenopus* embryos were homogenised in a hypotonic buffer (20 mM HEPES, pH 7.2 with complete™ EDTA free protease inhibitors), followed by three 5 sec bursts of sonication at 4°C. The homogenates were stored at -20 °C in single use aliquots until required.

*Enzyme treatments* - For deglycosylation experiments, embryo homogenates (half embryo equivalents) were denatured and treated with or without PNGaseF (New England Biolabs) according to manufacturer's instructions. For PI-PLC treatment, adherent HEK cells were incubated either in the absence or presence of 1 U/ml PI-PLC (Sigma) at 37°C for 1 h in HEPES-buffered saline composed of 156 mM NaCl, 3mM KCl, 2 mM MgSO<sub>4</sub>, 1.25 mM KH<sub>2</sub>PO<sub>4</sub>, 10

mM D-Glucose, 2 mM CaCl<sub>2</sub> and 10 mM HEPES (pH 7.4). The medium was then collected and concentrated 10-fold using an Amicon Ultra 4 centrifugal filter (10 kDa cut-off).

*Secretion assays* - HEK cells were transfected with plasmids encoding SpARC4 *myc* or SpARC4  $\Delta$ C *myc* and the media replaced with serum and antibiotic free media, 5 h post-transfection. Cells were cultured for 12-15 h before preparation of cell homogenates and collection of media. The latter were concentrated 10-fold using Amicon Ultra 4 centrifugal filter (10 kDa cut-off).

*Western blot analysis* - *Xenopus* embryo homogenates (0.33 equivalents) or HEK cell homogenates (25-50 µg protein), or media were reduced and denatured with 4 mM DTT at 90°C for 10 min and loaded onto NuPAGE 4–12% Bis-Tris gels (Invitrogen). The gel was run with either MOPS or MES running buffer (Invitrogen) and the resolved proteins transferred to a nitrocellulose membrane (Applied Biosystems). The blots were blocked with 5% dried skimmed non-fat milk powder dissolved in Tris-buffered saline (25 mM Tris,HCl 137 mM NaCl, 2.7 mM KCl, pH 7.4) supplemented with 0.1% Tween-20 (TBS-T) overnight at 4°C. The blot was washed 3 times with TBS-T and incubated with the primary antibody (mouse anti-Myc monoclonal antibody, clone 9e10; Insight Biotechnology; 1/1000 dilution) for 1 h at 25°C. Following a further 3 washes with TBS-T, the blot was incubated with the secondary antibody (anti-mouse IgG conjugated to horse radish peroxidase; Invitrogen; 1/1000 dilution) for 1 h at 25°C. The blots were developed either with Pierce ECL substrate (Thermo Scientific) or ECL™ Advanced System (GE Healthcare) according to manufacturer's guidelines

*Immunocytochemistry* - *Xenopus* embryos were fixed with 4% paraformaldehyde in phosphate-buffered saline (PBS) and stored at 4°C. The embryos were then permeabilised by 2 washes with Tris-buffered saline containing 0.1% Triton X-100 followed by 3 washes with TBS-T (30 min each). The embryos were then blocked with 20% goat serum in TBS-T for 1 h at room temperature. Embryos were incubated with the primary antibody (mouse anti-*myc* monoclonal antibody, clone 9e10; 1/100 dilution) overnight at 4°C in blocking solution. The embryos were

then washed 4 times with TBS-T containing 2 mg/ml BSA and blocked again in a solution containing TBS-T supplemented with 2 mg/ml BSA and 20% goat serum for 1 h. Embryos were incubated with the secondary antibody (goat polyclonal anti-mouse IgG conjugated with Cy-3; Zymed; 1/100 dilution) overnight at 4°C in the same blocking solution. The embryos were then washed 4 times with TBS-T containing 2 mg/ml BSA (30 min each).

For transfected HEK cells, cells were fixed in 4% paraformaldehyde in phosphate-buffered saline (PBS) for 10 min at 25°C followed by 3 washes with PBS at 25°C. The cells were permeabilised with PBS + 0.1% TX-100 for 10 min at 25°C with gentle agitation. The cells were then washed again (3 times with PBS) and incubated with blocking solution (5% foetal bovine serum and 1% bovine serum albumin in PBS) for 60 min at 25°C with gentle agitation. The coverslips were incubated with primary antibody (mouse monoclonal anti-*myc* 9e10; 1/100 dilution) in blocking solution at 37°C for 60 min followed by 3 washes with PBS + 0.1% Tween-20. The coverslips were then incubated with the secondary antibody (goat polyclonal anti-mouse IgG conjugated with Cy-3; 1/100 dilution) in blocking solution at 37°C for 60 min followed by 3 washes with PBS + 0.1% Tween-20. The coverslips were mounted on glass slides with DABCO, air dried and sealed with nail varnish. In some experiments, immunocytochemistry was performed using non-permeabilised cells. In these cases, live cells were incubated with the primary antibody in HEPES-buffered saline for 60 min at 4°C. The cells were then fixed, washed with PBS and incubated with the secondary antibody as described above.

*Confocal microscopy* - Fluorescence images of *Xenopus* embryos and HEK cells were captured using a Zeiss LSM 510 confocal microscope equipped with a 20x or 63x objective. The wavelengths for excitation and emission for Cy3 were 543 nm and 560–615 nm, respectively.

*Enzyme activity measurements* - *Xenopus* embryo homogenates (typically 20 µl) were diluted 5-fold into reaction mixes composed of either 1 mM NAD and 20 mM HEPES (pH 7.2), for the measurement of ADP-ribosyl cyclase activity or 1 mM NADP and 50 mM nicotinic acid (pH 4.8), for the measurement of base-exchange activity. The reactions were allowed to

proceed for up to 4h at room temperature, diluted 10-fold with water and heated at 60°C for 5 min. The mix was then centrifuged for 1 min at 21000 x g to remove any particulate matter. The supernatants were injected onto an AGMPI (Biorad) anion exchange HPLC column (3X150mm) at a flow rate of 1ml/min and bound nucleotides separated with a concave-up gradient of trifluoroacetic acid as described previously (25). Absorbance was recorded at 254 nm using a UV spectrophotometer and the areas of the resolved peaks calculated using Breeze Software (Waters). A mix of standards (1mM NAD, NADP, cADPR, NAADP) was separated in parallel for calibration.

## RESULTS

Our original BLAST queries of the *Stronglyocentrotus purpuratus* genome with known ADP-ribosyl cyclase sequences led to the isolation of SpARC1-3 (25). Here we report the molecular cloning of a new ADP-ribosyl cyclase herein named SpARC4. The full-length coding sequence was determined using a combination of 5'- and 3'-RACE (See Methods). SpARC4 is predicted to encode a polypeptide comprising 343 amino acids. An alignment of the deduced amino acid sequence of SpARC4 with those of SpARC1-3 is shown in Figure 1A. Sequence identity between SpARC4 and other family members was ~ 25 % and sequence similarity was ~ 40 % (Figure 1B). We also identified three ESTs from the sea urchin *Paracentrotus lividus* that were 65-66 % identical and 74 % similar to SpARC4 (Fig. S1). The 10 “core” cysteine residues found in *Aplysia* ADP-ribosyl cyclase are conserved in SpARC4 (Fig. 1A, asterisks). These data further highlight expansion of the ADP-ribosyl cyclase family.

SpARC4 is predicted to have an N-terminal signal peptide of 34 residues, 3 N-linked glycosylation sites (1 within the putative signal peptide) and a C-terminal GPI anchor (Fig. 1A). The predicted structure of SpARC4 is schematically depicted in Figure 2A. In order to define the properties of SpARC4, the series of expression constructs represented in Fig. 2B were generated. We first expressed the full-length *myc*-tagged SpARC4 (SpARC4 *myc*) in *Xenopus* embryos and HEK cells (Fig. 2C). Western blot analysis using an anti-*myc* antibody revealed the presence of a major polypeptide of ~55 kDa in embryos expressing SpARC4 *myc* (Fig. 2C). The apparent molecular mass of

SpARC4 *myc* was modestly reduced following treatment of homogenates with PNGase-F, which releases N-linked glycans (Fig. 2C). The size of the PNGase-F-treated protein was in reasonable agreement with the predicted molecular mass of mature SpARC4 *myc* (44 kDa). In HEK cells expressing SpARC4 *myc*, two major bands of approximately 55 kDa and 45 kDa were observed (Fig. 2C). Treatment with PNGase-F reduced the apparent molecular mass of the larger band but the migration of the lower band was not affected. The identity of the latter remains to be established but may correspond to unprocessed SpARC4. These data indicate that SpARC4 is N-glycosylated, consistent with the presence of consensus N-glycosylation sites.

To determine the subcellular localisation of SpARC4, we performed immunocytochemical analysis in conjunction with confocal microscopy. Fig. 2D shows the distribution of SpARC4 *myc* expressed in *Xenopus* embryos. Two patterns were observed; clear cell surface staining (Fig. 2D, top left), or a punctate intracellular distribution often concentrated at the periphery (Fig. 2F, top right). In these experiments, only a single blastomere of a 2-4 cell embryo was injected in order to effect mosaic expression. Indeed, cells which did not express the protein were clearly evident in embryos (Fig. 2D, asterisks) thereby defining background staining and thus attesting to specificity of the labelling. In HEK cells, SpARC4 localized mainly to the plasma membrane although diffuse intracellular staining was also evident (Fig. 2D, bottom left). Localisations were also performed using intact (non-permeabilized) cells (Fig. 2D, bottom right). Surface staining was readily detectable indicating that the epitope is extracellular further confirming plasma membrane residence of this protein.

Given the consensus sequence for GPI anchoring, we next examined the effect of bacterial phosphatidyl inositol-specific phospholipase C (PI-PLC), which releases GPI-anchored proteins from the plasma membrane. We first treated cells expressing SpARC4 *myc* with PI-PLC and analysed the media for SpARC immunoreactivity by Western blotting. As shown in Fig. 3A, this treatment resulted in the appearance of released SpARC4 *myc* in the medium. These data suggest that SpARC4 is attached to the plasma membrane by a GPI anchor. In parallel experiments, we examined cell surface expression of SpARC4 *myc* by

immunocytochemistry. As shown in Fig. 3B, PI-PLC treatment caused a reduction in expression of SpARC4, again consistent with the presence of a GPI-anchor. Finally, we deleted the C-terminus harbouring the putative GPI anchoring site and compared secretion of the full-length and truncated SpARC4 *myc*. As shown in Fig 3C, SpARC4  $\Delta$ C *myc* was present in the medium at higher levels than the full-length construct. Both constructs were expressed at comparable levels within cells (data not shown). These data suggest that SpARC4 is attached to the plasma membrane at its C-terminus via a GPI anchor.

We have previously used an HPLC assay and *Xenopus* embryos over-expressing SpARC1 and SpARC2 to characterize the enzymatic properties of the heterologously translated proteins (25). Here we use the same approach to characterize SpARC4. In the first set of experiments, homogenates expressing SpARC4 *myc* were incubated with NAD. As shown in the HPLC chromatogram in Fig 4A, NAD, after a 3 h incubation, was converted to a product with retention time of  $17.7 \pm 0.14$  min corresponding to that of cADPR ( $17.3 \pm 0.1$  min). ADP-ribose production was not routinely detected (retention time = 26 min) under these experimental conditions. We next tested whether SpARC4 could generate NAADP. For these experiments, homogenates were incubated with NADP and nicotinic acid under acidic conditions to favour the base-exchange reaction. As shown in Fig. 4B, NADP, after a 3 h incubation, was converted to a product (retention time =  $31.4 \pm 0.04$  min) that co-eluted with NAADP (retention time =  $31.3 \pm 0.03$  min). Thus, SpARC4 is capable of both the cyclisation and base-exchange reactions indicating that it is a *bona fide* multifunctional ADP-ribosyl cyclase.

A time-course for cADPR and NAADP production by SpARC4 is shown in Fig. 4C. Strikingly, SpARC4 *myc* produced markedly more cADPR than NAADP under these experimental conditions of saturating substrate concentrations. This is in direct contrast to SpARC1 and SpARC2 which, as previously reported (25), produce more NAADP than cADPR when assayed identically. The results with SpARC2 are confirmed here (Fig. 4D). The initial rates of cADPR and NAADP production are listed in Table 1. SpARC4 untagged also displayed the same preference for producing cADPR as SpARC4 *myc* (Table 1), indicating that the unusual catalytic activity associated with

SpARC4 was not a consequence of tagging the protein.

Inspection of the sequence downstream of the predicted signal peptide of SpARC4, revealed the presence of a cluster of acidic amino acids followed by basic residues (Fig. 1A, box). This acidic-basic cluster is unique to SpARC4 among ADP-ribosyl cyclases. To investigate the potential functional role of this cluster, we generated a construct in which the sequence was deleted (SpARC4  $\Delta N$  *myc*). This construct like the full-length construct was readily expressed in both *Xenopus* embryos and HEK cells (Fig. 5A). Immunocytochemical analysis indicated that it localised to the plasma membrane (Fig. 5B). Measurement of cADPR and NAADP production did not reveal any differences between SpARC4  $\Delta N$  *myc* and SpARC4 *myc*. (Fig. 5C). Thus, SpARC4  $\Delta N$  *myc* also preferentially produced cADPR (Fig. 5C, Table 1). We noted that the basic amino acids within the unique region of SpARC4 conform to a consensus sequence (RXXR) for cleavage by pro-convertase, raising the possibility that SpARC4 may be proteolytically processed. However, we could not detect the putative N-terminal cleaved product containing the *myc* tag (predicted size ~ 15 kDa) by Western blotting when gels were run under conditions to optimally resolve small proteins and when the blots were over developed (Fig. 5D). Additionally, a mutant construct (SpARC4<sup>R52A/R53A</sup> *myc*), in which arginine 52 and 53 were replaced with alanine (to disrupt the consensus cleavage site), was readily expressed (Fig. 5A), localized to the plasma membrane (Fig. 5B) and catalytically similar to SpARC4 *myc* (Fig 5C, Table 1). Taken together, the acidic-basic cluster appears not to affect the catalytic properties of SpARC4.

Several residues that form the active site of *Aplysia* ADP-ribosyl cyclase, CD38 and CD157 have been identified by site directed mutagenesis and structural studies. These include a tryptophan residue (at position 77 and 125 in *Aplysia* and human CD38, respectively) which is strictly conserved in these ADP-ribosyl cyclases (48;49). Intriguingly, multiple sequence alignment identifies a tyrosine residue at the corresponding position 142 of SpARC4, suggesting that this enzyme, in analogy with *Schistosoma mansoni* NACE (24) possesses a non-canonical active site (Fig. 6A). To assess the potential functional importance of tyrosine 142, we generated a mutant construct in which this

residue was replaced with tryptophan (SpARC4<sup>Y142W</sup> *myc*). We also generated a second construct in which tyrosine was replaced with histidine (SpARC4<sup>Y142H</sup> *myc*). The latter mutation corresponds to the residue found in *SmNACE* (Fig. 6A). Both mutant constructs were readily expressed in *Xenopus* embryos and HEK cells to comparable levels as the wild type construct (Fig. 6B). Additionally, both mutant constructs localized to the plasma membrane (Fig. 6C). Production of cADPR and NAADP for the two constructs is shown in Fig. 6D. Remarkably, whereas the wild type construct preferentially produced cADPR, production of cADPR and NAADP was comparable for SpARC4<sup>Y142W</sup> *myc* (Fig. 6D). Overall activity, however, was reduced relative to the wild type enzyme (Table 1). These data highlight a critical role for tyrosine 142 in determining both the catalytic efficiency of SpARC4 and the relative production of cADPR and NAADP. The results with SpARC4<sup>Y142H</sup> *myc* were even more striking. This single mutation greatly affected the ADP-ribosyl cyclase activity of SpARC4 without perturbing the transglycosidation process (Fig. 6D). Thus, there was a complete reversal in the preference for the different reactions such that the mutant cyclase preferentially produced NAADP (Fig. 6D, Table 1), very much like SpARC2 (Fig. 4D). The ratio of the initial rates of cADPR and NAADP production for the different constructs from several independent preparations is summarized in Fig. 7. This analysis has the advantage in that it is independent of the absolute expression levels of the constructs, which varies between preparations. These data show that production of cADPR and NAADP by SpARC4 is controlled by a single active site residue, which, when mutated, can convert SpARC4 into a SpARC2-like enzyme.

## DISCUSSION.

In the present study, we report the molecular cloning of an additional member of the ADP-ribosyl cyclase family, show that it is a glycoprotein targeted to the plasma membrane by a GPI-anchor and that it displays unusual catalytic activity dictated by a single active site residue.

Our understanding of the molecular diversity of ADP-ribosyl cyclases is currently limited. *Aplysia* and *Schistosoma* (protostomes) possess a single ADP-ribosyl cyclase gene

whereas mammals (deuterostomes) possess two. The sea urchin holds a key evolutionary position as a basal deuterostome and as a close relative of the chordates. We have previously characterized an expanded three member family of ADP-ribosyl cyclases in the sea urchin (25). Here we highlight further expansion of this family through the cloning of a fourth member, SpARC4. Comparative genomic analysis of ADP-ribosyl cyclases in other deuterostomes should provide insight into the unusual evolution of the ADP-ribosyl cyclase gene family in this lineage.

SpARC4, like SpARC2 (55), mammalian CD157 (23) and *SmNACE* (24), localizes to the plasma membrane via a GPI-anchor (Figs. 2-3), which contrasts to the intracellular location of SpARC1 (25). The ectocellular location of SpARC4 shared also by mammalian CD38 (22) further suggests that second messenger production may occur at extra-cellular sites. Whether SpARC4 (and SpARC2) is internalized, e.g. via endocytosis, as reported for CD38 (62) remains to be established, although we did note a punctate intracellular distribution of SpARC4 in some cells upon heterologous expression in *Xenopus* embryos which might indicate an endosomal location (Fig. 2).

A clear distinguishing feature of SpARC4 relates to its catalytic activity; under our experimental conditions, SpARC4 appears to produce predominantly cADPR (Fig. 4), whereas SpARC1 and SpARC2 preferentially produce NAADP (25;55). An unidentified enzyme present on the surface of sea urchin sperm also preferentially produces NAADP (63). Whilst much attention has focused on determining the relative rates of NAD cyclisation and glycohydrolase activity culminating recently in the effective interconversion of CD38 and *Aplysia* ADP-ribosyl cyclase by site-directed mutagenesis (58), little is known about what controls the relative production of cADPR and NAADP.

Elucidating the molecular basis for the pronounced difference in catalytic activity between SpARC4 and other family members represents a formidable challenge given the very modest sequence identity between them (Fig. 1B). We first focused on a cluster of acidic and basic amino acids in the N-terminus of SpARC4. This cluster is absent from other SpARCs. Interestingly, this region of the protein encompasses a consensus pro-convertase

cleavage sequence raising the possibility that SpARC4 may be proteolytically processed, which in turn may regulate catalysis. Indeed, cleavage at such sites in many other proteins including tollid metalloproteases is required for activity (64). However as shown in Fig. 5D, we could not detect cleavage of SpARC4 despite the presence of robust pro-protease activity in *Xenopus* embryos (65;66). Moreover, catalytic activity of SpARC4 was unaffected when the putative cleavage site was disrupted by site directed mutagenesis or when the N-terminus encompassing the site was deleted (Fig. 5C). Thus, this region of the enzyme appears to not affect catalysis. Its functional role remains to be defined.

Catalysis is thought to proceed via a partitioning kinetic mechanism (13;14;50) raising the possibility that active site residue(s) may control the cyclisation step relative to the base-exchange pathway. We therefore next focused on position 142 in SpARC4 where a tyrosine residue replaces tryptophan which is otherwise strictly conserved in the *Aplysia* enzyme, CD38 and CD157. This substitution was confirmed by ESTs from a different urchin species (Fig. S1) indicating that a fourth ADP-ribosyl cyclase is not unique to the purple sea urchin, and that the difference in sequence at this position was not due to a cloning error. The non-canonical active site described here for SpARC4 is also a feature of *SmNACE* (24). In *SmNACE*, the active site contains a histidine residue (His103) in place of this conserved tryptophan which in the other ADP-ribosyl cyclases has been implicated in substrate positioning (48;49). In the *Aplysia* enzyme and CD38, mutation of this residue substantially affects both ADP-ribosyl cyclase and base-exchange activity. Notably, studies on CD38 included mutation of tryptophan 125 to tyrosine thus producing a mutant enzyme similar to SpARC4 (49). Conversely, the ADP-ribosyl cyclase activity of *SmNACE*, which is undetectable with NAD as substrate, was dramatically increased upon mutation of the non-canonical active site histidine 103 to tryptophan (60). This effect was ascribed to the more polar environment in the wild-type enzyme favouring entry of water and thus hydrolysis of NAD, as opposed to the competing intramolecular cyclisation of NAD (60). In contrast, SpARC4 displays robust ADP-ribosyl cyclase activity relative to other SpARCs and is more active than its tryptophan mutant



(Fig. 6). These data suggest that other residues are likely to contribute to catalysis in SpARC4.

Despite the conservative nature of the substitution at the active site of SpARC4 (tryptophan to tyrosine), we show that this residue plays a critical role in determining the production of cADPR over NAADP. This is most pronounced in SpARC4<sup>Y142H</sup>, where the ADP-ribosyl cyclase activity was decreased by one order of magnitude but, in sharp contrast with SpARC4<sup>Y142W</sup>, the mutation did not affect the transglycosidation reaction. Consequently a complete switch in relative ADP-ribosyl cyclase and base-exchange activity is observed resulting in a catalytic profile very similar to SpARC1 and SpARC2 (Fig. 6). Previous mutagenesis analyses of *Aplysia* ADP-ribosyl cyclase and CD38 have generally focused on cyclase/glycohydrolase ratios and, where measured, base-exchange activity of the mutants tended to mirror changes in cyclase activity. One notable exception is

glutamate 146 in CD38, which when mutated did in some instances (e.g E146D and E146G) result in reciprocal changes in cyclase and base-exchange activity (59). Thus, this residue might also dictate the relative production of cADPR and NAADP.

The non-canonical active sites of *SmNACE* and SpARC4 are highly unusual. The presence of residues other than tryptophan at this position in ADP-ribosyl cyclases appears unique to these enzymes based on inspection of a variety of ADP-ribosyl cyclase sequences across phyla (data not shown). Thus, selection pressure appears to have been relaxed for these homologues. The resulting changes in activity in the sea urchin might be of particular significance given the multiplicity of isoforms in this organism. We speculate that different ADP-ribosyl cyclase isoforms with different activities might regulate specific cellular functions.

## REFERENCES

1. Berridge, M. J., Lipp, P., and Bootman, M. D. (2000) *Nat. Rev. Mol. Cell Biol.* **1**, 11-21
2. Lee, H. C. (2001) *Annu. Rev. Pharmacol. Toxicol.* **41**, 317-345
3. Guse, A. H. and Lee, H. C. (2008) *Sci. Signal.* **1**, re10
4. Galione, A., Lee, H. C., and Busa, W. B. (1991) *Science* **253**, 1143-1146
5. Guse, A. H. (2009) *Curr. Biol.* **19**, R521-R523
6. Lee, H. C. and Aarhus, R. (1995) *J. Biol. Chem.* **270**, 2152-2157
7. Berridge, G., Dickinson, G., Parrington, J., Galione, A., and Patel, S. (2002) *J. Biol. Chem.* **277**, 43717-43723
8. Churchill, G. C., Okada, Y., Thomas, J. M., Genazzani, A. A., Patel, S., and Galione, A. (2002) *Cell* **111**, 703-708
9. Patel, S. and Docampo, R. (2010) *Trends Cell Biol.*
10. Brailoiu, E., Churamani, D., Cai, X., Schrlau, M. G., Brailoiu, G. C., Gao, X., Hooper, R., Boulware, M. J., Dun, N. J., Marchant, J. S., and Patel, S. (2009) *J. Cell Biol.* **186**, 201-209
11. Calcraft, P. J., Ruas, M., Pan, Z., Cheng, X., Arredouani, A., Hao, X., Tang, J., Rietdorf, K., Teboul, L., Chuang, K. T., Lin, P., Xiao, R., Wang, C., Zhu, Y., Lin, Y., Wyatt, C. N., Parrington, J., Ma, J., Evans, A. M., Galione, A., and Zhu, M. X. (2009) *Nature* **459**, 596-600
12. Brailoiu, E., Hooper, R., Cai, X., Brailoiu, G. C., Keebler, M. V., Dun, N. J., Marchant, J. S., and Patel, S. (2010) *J. Biol. Chem.* **285**, 2897-2901
13. Lee, H. C., Munshi, C., and Graeff, R. (1999) *Mol. Cell Biochem.* **193**, 89-98
14. Schuber, F. and Lund, F. E. (2004) *Curr. Mol. Med.* **4**, 249-261
15. Partida-Sanchez, S., Cockayne, D. A., Monard, S., Jacobson, E. L., Oppenheimer, N., Garvy, B., Kusser, K., Goodrich, S., Howard, M., Harmsen, A., Randall, T. D., and Lund, F. E. (2001) *Nat. Med.* **7**, 1209-1216
16. Jin, D., Liu, H. X., Hirai, H., Torashima, T., Nagai, T., Lopatina, O., Shnayder, N. A., Yamada, K., Noda, M., Seike, T., Fujita, K., Takasawa, S., Yokoyama, S., Koizumi, K., Shiraishi, Y., Tanaka, S., Hashii, M., Yoshihara, T., Higashida, K., Islam, M. S., Yamada, N., Hayashi, K., Noguchi, N., Kato, I., Okamoto, H., Matsushima, A., Salmina, A., Munesue, T., Shimizu, N., Mochida, S., Asano, M., and Higashida, H. (2007) *Nature* **446**, 41-45
17. Clapper, D. L., Walseth, T. F., Dargie, P. J., and Lee, H. C. (1987) *J. Biol. Chem.* **262**, 9561-9568
18. Hellmich, M. R. and Strumwasser, F. (1991) *Cell Regul.* **2**, 193-202

19. Glick, D. L., Hellmich, M. R., Beushausen, S., Tempst, P., Bayley, H., and Strumwasser, F. (1991) *Cell Regul.* **2**, 211-218
20. Lee, H. C. and Aarhus, R. (1991) *Cell Regul.* **2**, 203-209
21. Aarhus, R., Graeff, R. M., Dickey, D. M., Walseth, T. F., and Lee, H. C. (1995) *J. Biol. Chem.* **270**, 30327-30333
22. Howard, M., Grimaldi, J. C., Bazan, J. F., Lund, F. E., Santos-Argumedo, L., Parkhouse, R. M. E., Walseth, T. F., and Lee, H. C. (1993) *Science* **262**, 1056-1059
23. Hirata, Y., Kimura, N., Sato, K., Oshugi, Y., Takasawa, S., Okamoto, H., Ishikawa, J., Kaisho, T., Ishihara, K., and Hirano, T. (1994) *FEBS Lett.* **356**, 244-248
24. Goodrich, S. P., Muller-Steffner, H., Osman, A., Moutin, M. J., Kusser, K., Roberts, A., Woodland, D. L., Randall, T. D., Kellenberger, E., Loverde, P. T., Schuber, F., and Lund, F. E. (2005) *Biochemistry* **44**, 11082-11097
25. Churamani, D., Boulware, M. J., Geach, T. J., Martin, A. C., Moy, G. W., Su, Y. H., Vacquier, V. D., Marchant, J. S., Dale, L., and Patel, S. (2007) *PLoS. ONE.* **2**, e797
26. De Flora, A., Zocchi, E., Guida, L., Franco, L., and Bruzzone, S. (2004) *Ann. N. Y. Acad. Sci.* **1028**, 176-191
27. Davis, L. C., Morgan, A. J., Ruas, M., Wong, J. L., Graeff, R. M., Poustka, A. J., Lee, H. C., Wessel, G. M., Parrington, J., and Galione, A. (2008) *Curr. Biol.* **18**, 1612-1618
28. Bezin, S., Charpentier, G., Lee, H. C., Baux, G., Fossier, P., and Cancela, J. M. (2008) *J. Biol. Chem.* **283**, 27859-27870
29. Kato, I., Yamamoto, Y., Fujimura, M., Noguchi, N., Takasawa, S., and Okamoto, H. (1999) *J. Biol. Chem.* **274**, 1869-1872
30. Fukushi, Y., Kato, I., Takasawa, S., Sasaki, T., Ong, B. H., Sato, M., Ohsaga, A., Sato, K., Shirato, K., Okamoto, H., and Maruyama, Y. (2001) *J. Biol. Chem.* **276**, 649-655
31. Kim, S. Y., Cho, B. H., and Kim, U. H. (2010) *J. Biol. Chem.* **285**, 576-582
32. Ceni, C., Muller-Steffner, H., Lund, F., Pochon, N., Schweitzer, A., De Waard, M., Schuber, F., Villaz, M., and Moutin, M. J. (2003) *J. Biol. Chem.* **278**, 40670-40678
33. Soares, S., Thompson, M., White, T., Isbell, A., Yamasaki, M., Prakash, Y., Lund, F., Galione, A., and Chini, E. N. (2006) *Am. J. Physiol Cell Physiol* **292**, C227-C239
34. Meszaros, L. G., Wrenn, R. W., and Varadi, G. (1997) *Biochem. Biophys. Res. Commun.* **234**, 252-256
35. Matsumura, N. and Tanuma, S. (1998) *Biochem. Biophys. Res. Commun.* **253**, 246-252
36. Guse, A. H., da Silva, C. P., Berg, I., Skapeno, A. L., Weber, K., Heyer, P., Hohenegger, M., Ashamu, G. A., Schulze-Koops, H., Potter, B. V. L., and Mayr, G. W. (1999) *Nature* **398**, 70-73
37. Wilson, H. L., Dipp, M., Thomas, J. M., Lad, C., Galione, A., and Evans, A. M. (2001) *J. Biol. Chem.* **276**, 11180-11188
38. Hohenegger, M., Suko, J., Gscheidlinger, R., Drobny, H., and Zidar, A. (2002) *Biochem. J.* **367**, 423-431
39. Bruzzone, S., De Flora, A., Usai, C., Graeff, R., and Lee, H. C. (2003) *Biochem. J.* **375**, 395-403
40. Sternfeld, L., Krause, E., Guse, A. H., and Schulz, I. (2003) *J. Biol. Chem.* **278**, 33629-33636
41. Xie, G. H., Rah, S. Y., Kim, S. J., Nam, T. S., Ha, K. C., Chae, S. W., Im, M. J., and Kim, U. H. (2005) *Biochem. Biophys. Res. Commun.* **330**, 1290-1298
42. Zhang, F., Zhang, G., Zhang, A. Y., Koeberl, M. J., Wallander, E., and Li, P. L. (2006) *Am. J. Physiol Heart Circ. Physiol* **291**, H274-H282
43. Billington, R. A., Harper, C., Bellomo, E. A., Publicover, S., Barratt, C. L., and Genazzani, A. A. (2006) *Fertil. Steril.* **86**, 891-898
44. Graeff, R. M., Franco, L., De Flora, A., and Lee, H. C. (1998) *J. Biol. Chem.* **273**, 118-125
45. Prasad, G. S., McRee, D. E., Stura, E. A., Levitt, D. G., Lee, H. C., and Stout, C. D. (1996) *Nat. Struct. Biol.* **3**, 957-964
46. Yamamoto-Katayama, S., Ariyoshi, M., Ishihara, K., Hirano, T., Jingami, H., and Morikawa, K. (2002) *J. Mol. Biol.* **316**, 711-723
47. Liu, Q., Kriksunov, I. A., Graeff, R., Munshi, C., Lee, H. C., and Hao, Q. (2006) *J. Biol. Chem.* **281**, 32861-32869

48. Munshi, C., Thiel, D. J., Mathews, I. I., Aarhus, R., Walseth, T. F., and Lee, H. C. (1999) *J. Biol. Chem.* **274**, 30770-30777
49. Munshi, C., Aarhus, R., Graeff, R., Walseth, T. F., Levitt, D., and Lee, H. C. (2000) *J. Biol. Chem.* **275**, 21566-21571
50. Cakir-Kiefer, C., Muller-Steffner, H., and Schuber, F. (2000) *Biochem. J.* **349**, 203-210
51. Perraud, A. L., Fleig, A., Dunn, C. A., Bagley, L. A., Launay, P., Schmitz, C., Stokes, A. J., Zhu, Q., Bessman, M. J., Penner, R., Kinet, J. P., and Scharenberg, A. M. (2001) *Nature* **411**, 595-599
52. Lange, I., Yamamoto, S., Partida-Sanchez, S., Mori, Y., Fleig, A., and Penner, R. (2009) *Sci. Signal.* **2**, ra23
53. Patel, S. and Docampo, R. (2009) *Sci. Signal.* **2**, e69
54. Graeff, R. M., Walseth, T. F., Fryxell, K., Branton, W. D., and Lee, H. C. (1994) *J. Biol. Chem.* **269**, 30260-30267
55. Churamani, D., Boulware, M. J., Ramakrishnan, L., Geach, T. J., Martin, A. C., Vacquier, V. D., Marchant, J. S., Dale, L., and Patel, S. (2008) *Cell Signal.* **20**, 2347-2355
56. Tohgo, A., Takasawa, S., Noguchi, N., Koguma, T., Nata, K., Sugimoto, T., Furuya, Y., Yonekura, H., and Okamoto, H. (1994) *J. Biol. Chem.* **269**, 28555-28557
57. Zhang, B., Muller-Steffner, H., Schuber, F., and Potter, B. V. (2007) *Biochemistry* **46**, 4100-4109
58. Graeff, R., Liu, Q., Kriksunov, I. A., Kotaka, M., Oppenheimer, N., Hao, Q., and Lee, H. C. (2009) *J. Biol. Chem.* **284**, 27629-27636
59. Graeff, R., Munshi, C., Aarhus, R., Johns, M., and Lee, H. C. (2001) *J. Biol. Chem.* **276**, 12169-12173
60. Kuhn, I., Kellenberger, E., Rognan, D., Lund, F. E., Muller-Steffner, H., and Schuber, F. (2006) *Biochemistry* **45**, 11867-11878
61. Sive, H. L., Grainger, R. M., and Harland, R. M. (2000) *Early development of Xenopus laevis: a laboratory manual.*, Cold Spring Harbor Press, Cold Spring Harbor, NY
62. Zocchi, E., Franco, L., Guida, L., Piccini, D., Tacchetti, C., and De Flora, A. (1996) *FEBS Lett.* **396**, 327-332
63. Vasudevan, S. R., Galione, A., and Churchill, G. C. (2008) *Biochem. J.* **411**, 63-70
64. Leighton, M. and Kadler, K. E. (2003) *J. Biol. Chem.* **278**, 18478-18484
65. Birsoy, B., Berg, L., Williams, P. H., Smith, J. C., Wylie, C. C., Christian, J. L., and Heasman, J. (2005) *Dev* **132**, 591-602
66. Nelsen, S., Berg, L., Wong, C., and Christian, J. L. (2005) *Dev. Dyn.* **233**, 1038-1044

## FOOTNOTES

We thank Dev Churamani for help with confocal microscopy, and George Dickinson and Chi Li for useful discussions. This work was supported by grants BB/D018110/1 and BB/G013721/1 from the Biotechnology and Biological Sciences Research Council (to S.P.) and a PhD studentship from the Medical Research Council (to L.R.).

The abbreviations used are. cADPR, cyclic ADP-ribose; NAADP, nicotinic acid adenine dinucleotide phosphate; HEK, Human embryonic kidney; TBS-T, Tris-buffered saline supplemented with 0.1% Tween-20; PBS, phosphate-buffered saline.

## FIGURE LEGENDS

**Figure 1. Molecular cloning of a novel member of the ADP-ribosyl cyclase family.** A, Multiple sequence alignment of the deduced amino acid sequences of SpARC4 and that of previously identified ADP-ribosyl cyclases from *Strongylocentrotus purpuratus* (SpARC1-3). Putative cleavage sites of the predicted signal peptide and GPI-anchor are marked with the filled and open arrow heads, respectively. The presence of an acidic-basic cluster of amino acids in SpARC4 is marked with a box. Conserved cysteine residues between isoforms are marked with an asterisk. B, Table showing percentage sequence identities (shaded) and percentage sequence similarities (above diagonal) derived from pair-wise alignments between SpARC family members.

**Figure 2. SpARC4 is a glycoprotein targeted to the plasma membrane.** A, Predicted structure of SpARC4. Putative N-linked glycosylation sites are marked with a “Y”. B, Schematic of the constructs used in this study. C, Western blot analysis, using an anti-*myc* antibody, of *Xenopus* embryos (left) or HEK cells (right) expressing *myc*-tagged SpARC4 (SpARC4 *myc*). Samples were untreated (-), mock treated or digested with PNGase F prior to analysis. Migration of molecular mass markers (in kDa) is shown on the left of the panel. D, Confocal fluorescence images of *Xenopus laevis* embryos (top) or HEK cells (bottom) expressing SpARC4 *myc*. Expression was detected by immunocytochemistry using an anti-*myc* primary antibody. For embryos, the images are typical of the two distribution patterns observed. The asterisks highlight cells not expressing the protein. For HEK cells, both permeabilized and non-permeabilized cells were processed. Scale bar = 5  $\mu$ m.

**Figure 3. SpARC4 is a GPI-anchored protein.** HEK cells expressing SpARC4 *myc* were treated with (+) or without (-) PI-PLC and the presence of SpARC4 determined in media samples by Western blot analysis (A) and on the cell surface by immunocytochemistry (B). Scale bar = 50  $\mu$ m. C, Western blot analysis of media samples from HEK cells expressing SpARC4 *myc* or *myc*-tagged SpARC4 lacking the C-terminal 17 amino acids (SpARC4  $\Delta$ C *myc*).

**Figure 4. SpARC4 is a multifunctional ADP-ribosyl cyclase.** A-B, Homogenates prepared from *Xenopus* embryos expressing SpARC4 *myc* were incubated with 1 mM NAD (A) or 1 mM NADP + 50 mM nicotinic acid (B) and the reaction mixes separated by HPLC. Typical chromatograms after a 0.1 h (black traces) or 3 h (red traces) incubation are shown. C-D, Time courses for production of cADPR (circles) and NAADP (squares) by *Xenopus* embryo homogenates expressing SpARC4 *myc* (C) and SpARC2 *myc* (D).

**Figure 5. Lack of effect of the acidic-basic cluster on SpARC4 activity.** A, Western blot analysis of *Xenopus* embryos (left) or HEK cells (right) expressing *myc*-tagged SpARC4 lacking either the N-terminal 17 amino acids (SpARC4  $\Delta$ N *myc*) or in which arginines 52 and 53 were mutated to alanine (SpARC4<sup>R52A/R53A</sup> *myc*). SpARC4 *myc* was analyzed in parallel. B, Immunocytochemical localisation of SpARC4  $\Delta$ N *myc* and SpARC4<sup>R52A/R53A</sup> *myc* in HEK cells. Scale bar = 5  $\mu$ m. C, Time-courses for production of cADPR and NAADP by SpARC4 *myc*, SpARC4  $\Delta$ N *myc* and SpARC4<sup>R52A/R53A</sup> *myc*. D, Western blot analysis of SpARC4 *myc* and SpARC4<sup>R52A/R53A</sup>. Arrow head marks the expected migration of the putative cleavage product. Blots were deliberately overexposed.


**Figure 6. Regulation of SpARC4 activity by non-canonical active site residue.** A, multiple sequence alignment of ADP-ribosyl cyclases showing lack of conservation of an active site tyrosine (asterisk) in SpARC4 and *Schistosoma* ADP-ribosyl cyclase. Abbreviations used: Ac, *Aplysia californica*; Hs, *Homo sapiens*; Sm, *Schistosoma mansoni*; Sj, *Schistosoma japonica*. B, Western blot analysis of *Xenopus* embryos (left) or HEK cells (right) expressing SpARC4 *myc* or *myc*-tagged SpARC4 in which tyrosine 142 was mutated to either tryptophan (SpARC4<sup>Y142W</sup> *myc*) or histidine (SpARC4<sup>Y142H</sup> *myc*). C, Immunocytochemical localisation of SpARC4<sup>Y142W</sup> *myc* and SpARC4<sup>Y142H</sup> *myc* in HEK cells. Scale bar = 5  $\mu$ m. D, Time-courses for production of cADPR and NAADP by SpARC4 *myc*, SpARC4<sup>Y142W</sup> *myc* and SpARC4<sup>Y142H</sup> *myc*.

**Figure 7. Summary of mutational analysis on SpARC4 activity.** Pooled data showing the ratio of ADP-ribosyl cyclase to base-exchange activity for the indicated construct. Data are presented as mean  $\pm$  standard error of the mean from 3-6 independent *Xenopus* embryo preparations.

| Construct                              | cADPR production<br>(nmoles/h/embryo) | NAADP production<br>(nmoles/h/embryo) | n |
|--|---------------------------------------|---------------------------------------|---|
| SpARC4 <i>myc</i>                      | 2.61 ± 0.49                           | 0.77 ± 0.16                           | 9 |
| SpARC4 untagged                        | 2.96 ± 1.19                           | 1.02 ± 0.51                           | 3 |
| SpARC4 ΔN <i>myc</i>                   | 3.9 ± 0.85                            | 1.36 ± 0.32                           | 3 |
| SpARC4 <sup>R52A/R53A</sup> <i>myc</i> | 2.19 ± 0.42                           | 0.97 ± 0.09                           | 3 |
| SpARC4 <sup>Y142W</sup> <i>myc</i>     | 0.13 ± 0.02                           | 0.15 ± 0.03                           | 3 |
| SpARC4 <sup>Y142H</sup> <i>myc</i>     | 0.1 ± 0.04                            | 1.06 ± 0.24                           | 3 |
| SpARC2 <i>myc</i>                      | 0.05 ± 0.01                           | 0.39 ± 0.07                           | 6 |

Table 1. Initial rates of cADPR and NAADP production. Data are presented as mean ± standard error of the mean from the indicated number of independent *Xenopus* embryo preparations.

A



B

|        | SpARC1     | SpARC2     | SpARC3     | SpARC4     |
|--------|------------|------------|------------|------------|
| SpARC1 | <b>100</b> | 66         | 35         | 39         |
| SpARC2 | 52         | <b>100</b> | 38         | 42         |
| SpARC3 | 23         | 21         | <b>100</b> | 39         |
| SpARC4 | 25         | 26         | 24         | <b>100</b> |

Figure 2






Figure 3




Figure 4







Figure 5






Figure 6




Figure 7

